# NCT04987203 (NCT04987203)

> Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04987203
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AVEO Pharmaceuticals, Inc.
- Conditions: Renal Cell Carcinoma
- Interventions: Tivozanib; Nivolumab
- Enrollment: 343
- Primary outcome: Progression free survival

## Commentary we found

- X threads: 97
- YouTube: 56
- Podcasts: 30
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04987203

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04987203", "email": "<work email>"}; the inbox owner confirms by the emailed link.